Related stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Related stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Management s Discussion and Analysis of Financial Condition and Results of Operations, but are also contained elsewhere in this Annual Report. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the…
The business is unprofitable at the operating level (-1735.70% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 79.8% YoY. Margins deteriorated 1433.7pp alongside, both lines moving the wrong way.
ROIC dropped from -304.17% to -2659.30%, capital efficiency is deteriorating. Negative free cash flow of -$26M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$3M
▼ -79.8% YoY
Net Income (TTM)
-$26M
▼ -5.7% YoY
Op. Margin
-689.76%
▼ -1433.7pp YoY
ROIC
-3153.41%
▼ -2355.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$22M
▼ -28.9% YoY
Op. Cash Flow (TTM)
-$21M
▼ -36.2% YoY
Net Debt
-$6M
Net Cash Position
Cash & Equiv.
$7M
5Y CAGR: -5.2%
Continue Research